Clinical trial approval / initiation

Explore the landscape of Clinical trial approval / initiation in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Clinical trial approval / initiation to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Innovent's Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003
Others

Innovent’s Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003

Innovent Biologics, Inc. (HKG: 1801) announced that the marketing application for a new indication of its PD‑1 inhibitor sintilimab (brand name: Tyvyt) has been accepted by China's National Medical Products…

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors
CompanyDrug

Junshi Biosciences Receives NMPA Approval for JS212 in Advanced Solid Tumors

Joyo Pharma's JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment
CompanyDrug

Joyo Pharma’s JYP0035 Receives Clinical Trial Approval for Breast Cancer Treatment

Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes
CompanyDrug

Tonghua Dongbao Initiates Phase III Trial for Insulin Degludec, Liraglutide Combo in Type 2 Diabetes

Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401
CompanyDrug

Livzon Pharmaceutical Receives Approval for Clinical Trials of Adjuvanted Influenza Vaccine LZSN2401

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia
CompanyDrug

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia

Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study
CompanyDrug

Frontera Therapeutics Receives NMPA Approval for FT-003 in Diabetic Retinopathy Study

Doma Biopharmaceutical's HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval
CompanyDrug

Doma Biopharmaceutical’s HER3-MUC1 Targeted ADC DM002 Receives NMPA Clinical Approval

CSPC Pharmaceutical Group Receives FDA Approval for SYH2051 Clinical Trial
CompanyDrug

CSPC Pharmaceutical Group Receives FDA Approval for SYH2051 Clinical Trial

Show More